News Releases

Date Title and Summary Additional Formats
Toggle Summary Sarepta Therapeutics Enters into Research Agreement and Option Agreement with Nationwide Children’s Hospital for Microdystrophin Gene Therapy Program
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 10, 2017-- Sarepta Therapeutics , Inc. (NASDAQ:SRPT), a commercial stage developer of innovative RNA-targeted therapeutics, today announced it has entered a research and option agreement with Nationwide Children’s Hospital on their microdystrophin gene
View HTML
Toggle Summary Sarepta Therapeutics to Present Company Overview at the 2017 35th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 3, 2017-- Sarepta Therapeutics , Inc. (NASDAQ:SRPT), a commercial stage developer of innovative RNA-targeted therapeutics, today announced that it is scheduled to present at the 35 th  Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday,
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 30, 2016-- Sarepta Therapeutics , Inc. (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, granted equity awards on December 30, 2016 , that were previously approved by the Compensation Committee of its Board of Directors
View HTML
Toggle Summary Sarepta Therapeutics Announces EMA Validation of Eteplirsen Authorization Application for Treatment of Duchenne Muscular Dystrophy Amenable to Exon Skipping 51
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 19, 2016-- Sarepta Therapeutics , Inc. (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, today announced that the European Medicines Agency (EMA) validated the previously submitted Marketing Authorization application (MAA)
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 30, 2016-- Sarepta Therapeutics , Inc. (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, granted equity awards on November 30, 2016 , that were previously approved by the Compensation Committee of its Board of Directors
View HTML
Toggle Summary Sarepta Therapeutics to Present Company Overview at the Credit Suisse 25th Annual Healthcare Conference
Webcast Accessible via Sarepta Therapeutics Website CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 4, 2016-- Sarepta Therapeutics  (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, announced today that it is scheduled to present at the Credit Suisse 25 th Annual
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 31, 2016-- Sarepta Therapeutics , Inc. (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, granted equity awards on October 31, 2016 , that were previously approved by the Compensation Committee of its Board of Directors
View HTML
Toggle Summary Sarepta Therapeutics Announces Third Quarter 2016 Financial Results and Recent Corporate Developments
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 27, 2016-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, today reported financial results for the three and nine months ended September 30, 2016 .
View HTML
Toggle Summary Sarepta Therapeutics to Announce Third Quarter 2016 Financial Results and Recent Corporate Developments on October 27, 2016
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 24, 2016-- Sarepta Therapeutics , Inc. (NASDAQ: SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, will report third quarter 2016 financial results before the NASDAQ Global Market opens on Thursday, October 27, 2016.
View HTML
Toggle Summary Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy
Sarepta and Summit collaborate to advance the development of novel therapies for patients with Duchenne muscular dystrophy Summit receives $40 million upfront, with potential future ezutromid-related milestone payments totalling up to $522 million plus royalties Sarepta and Summit to share research
View HTML

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.

There are no items to display.